Skip to main content

Table 1 Baseline characteristics of the sample

From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Characteristics Whole sample
Total (n = 1097)
Low MCP-1
(n = 823)
High MCP-1a
(n = 274)
Low Aβ42/40
(n = 137)
High Aβ42/40b
(n = 292)
Women, No. (%)d 700 (63.81%) 531 (64.52%) 169 (61.68%) 182 (73.09%) 110 (61.11%)
Age, yearsc,d 75.30 (4.37) 74.94 (4.21) 76.38 (4.66) 76.49 (4.77) 75.40 (4.44)
MAPT group allocation, No. (%)d
 Omega 3 + MDI group 274 (24.98%) 212 (25.76%) 62 (22.63%) 87 (29.79%) 27 (19.71%)
 Omega 3 group 267 (24.34%) 203 (24.67%) 64 (23.36%) 64 (21.92%) 37 (27.01%)
 MDI group 277 (25.25%) 198 (24.06%) 79 (28.83%) 77 (26.37%) 27 (19.71%)
 Control group 279 (25.43%° 210 (25.52%) 69 25.18%) 64 (21.92%) 46 (33.58%)
Education, No. (%)d
 No diploma 49 (4.54%) 37 (4.57%) 12 (4.43%) 4 (2.96%) 13 (4.51%)
 Primary school certificate 179 (16.57%) 133 (16.44%) 46 (16.97%) 38 (28.15%) 47 (16.32%)
 Secondary education 354 (32.78%) 256 (31.64%) 98 (36.16%) 52 (38.52%) 84 (29.17%)
 High school diploma 168 (15.56%) 135 (16.69%) 33 (12.18%) 10 (7.41%) 51 (17.71%)
 University level 330 (30.56%) 248 (30.66%) 82 (30.26%) 31 (22.96%) 93 (32.29%)
Body mass indexc,e 26.21 (4.05) 26.03 (3.95) 26.75 (4.32) 26.11 (3.51) 26.58 (4.23)
Composite cognitive scorec,f 0.023 (0.69) 0.05 (0.67) −0.05 (0.75) −0.22 (0.73) −0.11 (0.75)
CDR Sum of boxes, range 0–18c 0.39 (0.59) 0.35 (0.55) 0.49 (0.69) 0.53 (0.66) 0.47 (0.67)
CDR status, No. (%)c
 No cognitive impairment, CDR score, 0 580 (52.97%) 456 (55.47%) 124 (45.42%) 151 (98.69%) 86 (98.85%)
 Mild cognitive impairment, CDR score, 0.5 509 (46.48%) 362 (44.04%) 147 (53.85%) 2 (1.31%) 1 (1.15%)
 Major cognitive impairment, CDR score, ≥ 1 6 (0.55%) 4 (0.49%) 2 (0.73%) 0 (0%) 0 (0%)
MMSE score, range 0–30 28.07 (1.81) 28.10 (1.74) 27.98 (2.01) 27.61 (1.88) 27.92 (1.92)
FCSRT free recall, range 0–48c,d 30.38 (7.52) 30.77 (7.17) 29.23 (8.39) 27.54 (8.42) 29.25 (7.86)
FCSRT total recall, range 0–48 45.72 (3.80) 45.83 (3.56) 45.40 (4.42) 44.45 (4.85) 45.38 (4.71)
FCSRT free delayed recall, range 0–16 11.48 (2.99) 11.53 (2.90) 11.33 (3.26) 10.47 (3.48) 10.95 (3.08)
FCSRT total delayed recall, range 0–16 15.52 (1.25) 15.53 (1.22) 15.46 (1.33) 15.19 (1.55) 15.37 (1.58)
APOE ε4 genotype, No. (%)d
 APOE ε4 carriers 226 (22.89%) 168 (20.4%) 58 (21.2%) 45 (33.83%) 58 (22.83%)
 Non-APOE ε4 carriers 761 (77.11%) 572 (79.6%) 189 (79.8%) 88 (66.17%) 196 (77.17%)
  1. Abbreviations: Amyloid-β, ADCS-ADL Alzheimer Disease Cooperative Study–Activities of Daily Living, APOE Apolipoprotein E, CDR Clinical Dementia Rating, MDI Multi-Domain Intervention, MMSE Mini-Mental State Examination
  2. aHigh-plasma MCP-1 defined as values in the 4th quartile
  3. bLow-plasma Aβ42/40 defined as values ≤ 0.107
  4. cP < .05 based on Student t test or Pearson χ2 test (between MCP-1 groups)
  5. dP < .05 based on Student t test or Pearson χ2 test (between Aβ42/40 groups)
  6. eBody mass index calculated as weight in kilograms divided by height in meters squared
  7. fBased on the z-score of 4 cognitive tests (free and total recall of the Free and Cued Selective Reminding test, 10 MMSE orientation items, Digit Symbol Substitution Test, and Category Naming Test)